Author:
Kim Hye-Youn,Kim Jinhee,Ha Thi Huyen Trang,Bang Ok-Sun,Lee Won-Suk,Hong Suntaek
Funder
Korea Institute of Oriental Medicine
Ministry of Health and Welfare
Gachon University Gil Medical Center
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,General Medicine
Reference39 articles.
1. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489–99.
2. Buyse M, Thirion P, Carlson R, Burzykowski T, Molenberghs G, Piedbois P. Tumour response to first line chemotherapy improves the survival of patients with advanced colorectal cancer. Lancet. 2000;356:373–8.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14.
4. Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.
5. Knight R, Miller L, Pirotta N, Elfring G, Locker P, Saltz L. First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators. Proc Am Soc Clin Oncol. 2000;19:991a.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献